Korro Bio (NASDAQ:KRRO) aims to "discover, develop and commercialize a new class of RNA therapies informed by human genetics ...
Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECHâ„¢ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...
The first two and some forms of obesity are associated with single-point mutations. Some other companies using ADAR enzymes ...
H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Korro Bio (KRRO – Research Report) today and set a price target of ...
Korro Bio Inc. has announced a submission to the Australian Bellberry Human Research Ethics Committee (HREC) for a phase I/II study of KRRO-110 for α-1 antitrypsin deficiency (AATD).
Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Korro Bio (KRRO – Research Report) today and set a price target of ...
Antitrypsin Deficiency (AATD) submitted to Australian Bellberry Human Research Ethics Committee (HREC) -Clinical Advisory Board of lung and liver experts formed to support development of KRRO-110 ...
Vertex may have pivoted away from the space, but candidates in development by Arrowhead/Takeda, Wave, Korro and others could ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Korro Bio, Inc. (NASDAQ:KRRO), a biotechnology company specializing in RNA editing, is making significant strides in the development of genetic medicines, particularly for Alpha-1 Antitrypsin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback